Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Design Therapeutics, Inc.NASDAQ: DSGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $157K fell 1.3% year over year, behind the +1.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.3% toward the trailing-twelve-month pace of +1.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 622K USD
- Year-over-year change
- +4.4%
- 4-year CAGR
- +48.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 622K | +4.4% |
| FY2024 | 2024-12-31 | 596K | +11.0% |
| FY2023 | 2023-12-31 | 537K | +15.2% |
| FY2022 | 2022-12-31 | 466K | +261.2% |
| FY2021 | 2021-12-31 | 129K | — |
Depreciation & Amortization vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 depreciation & amortization of $620K is the 10th highest of the 11 companies compared; the peer median is $3.37M.
- Its year-over-year change of +1.3% is the 7th highest of 11, against a peer median of +5.1%.
- Over three fiscal years its annual growth of +10.1% compares with a peer median of +1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Mar 2026 | $45.14M | +15.9% | +2.1% | 2.1% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $8.99M | +4.0% | -4.3% | 12.5% | |
| LTM Mar 2026 | $3.54M | +69.2% | +4.6% | 11.0% | |
| LTM Mar 2026 | $3.2M | -40.7% | +41.5% | — | |
| LTM Jun 2026 | $2.15M | +13.8% | +6.8% | — | |
| LTM Mar 2026 | $1.62M | -35.9% | -12.1% | — | |
| LTM Mar 2026 | $1.38M | -6.3% | -16.8% | — | |
| LTM Mar 2026 | $620K | +1.3% | +10.1% | — | |
| LTM Mar 2026 | $326K | +0.0% | +3.2% | — | |
| Peer median (excluding DSGN) | $3.37M | +5.1% | +1.5% | 5.5% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.